A Randomized, Open-Label, Controlled, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Trial Profile

A Randomized, Open-Label, Controlled, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of Adecatumumab Alone or Sequentially to FOLFOX Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2014

At a glance

  • Drugs Adecatumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 10 Nov 2011 Actual patient number is 35 according to ClinicalTrials.gov.
    • 10 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Actual end date (November 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top